• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

ASCRS Live: Jim Mazzo, executive chair of Neurotech Pharmaceuticals shares company updates

Video

Jim Mazzo, executive chairman of Neurotech Pharmaceuticals, discussed the company's goal to slow down the progression of MacTel and their recent advancements at the ASCRS annual meeting in San Diego.

Jim Mazzo, Executive Chair of Neurotech Pharmaceuticals discussed the company's goal to slow down the progression of MacTel and their recent advancements at the ASCRS annual meeting in San Diego.

Video transcript

Editor’s note: Transcript lightly edited for clarity.

Jim Mazzo:

I am Jim Mazzo, Executive Chair out here at the ASCRS meeting, and some exciting news at Neurotech. You've probably been able to follow our journey over the years, but our journey is really moving forward very aggressively. Our whole goal is to slow down the progression of MacTel.

And I'm so pleased with what the team has been able to do through our innovative encapsulated cell therapy. We have such a unique device to be able to listen to drug to be able to slow down this terrible disease. We're moving fast. We've really accomplished a lot, but we need to do more. and we're really looking forward to working with these great retinal surgeons, rich small are CEO and the whole team have done a fantastic job. You need to pay attention to what's happening in neuro Tech because you're gonna see more and hear more from us in the future. Thanks so much for listening.

Related Videos
Neda Nikpoor, MD, talks about the Light Adjustable Lens at ASCRS 2024
Elizabeth Yeu, MD, highlights from a corneal case report for a patient undergoing the triple procedure
© 2024 MJH Life Sciences

All rights reserved.